- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Ibodutant 10 mg, Placebo
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 65
- States / cities
- Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- MEN1611, Trastuzumab, Fulvestrant
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Ibodutant 10 mg, Placebo
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
- Conditions
- Colic
- Interventions
- Nepadutant
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 2 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
- Interventions
- Samuraciclib, Elacestrant Dihydrochloride
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 2 more
- Conditions
- Ovarian Cancer
- Interventions
- Abagovomab, Placebo
- Biological
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 888 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 17 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- MEN1611, Cetuximab
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Anaheim, California • Tacoma, Washington
- Conditions
- Infantile Colic, Infantile Functional Gastrointestinal Disorders
- Interventions
- Nepadutant
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 6 Weeks to 24 Weeks
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Louisville, Kentucky • Cleveland, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- MEN1703
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Cleveland, Ohio • Portland, Oregon + 4 more
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
- Interventions
- Capecitabine, Elacestrant
- Drug
- Lead sponsor
- Kristina A. Fanucci
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts